Periodical
Phase 1b/2 Study of the First-in-Class SUMO-Activating Enzyme Inhibitor TAK-981 in Combination with Monoclonal Antibodies in Patients with Triple-Class Refractory Multiple Myeloma
| العنوان: | Phase 1b/2 Study of the First-in-Class SUMO-Activating Enzyme Inhibitor TAK-981 in Combination with Monoclonal Antibodies in Patients with Triple-Class Refractory Multiple Myeloma |
|---|---|
| المؤلفون: | Lonial, Sagar, Tarantolo, Stefano R., Boccia, Ralph V., Yimer, Habte, Levy, Moshe Y., Abonour, Rafat, Mohan, Meera, Roy, Vivek, Larsen, Jeremy T., Girnius, Saulius K., Rosenbaum, Cara A., Nadeem, Omar, Berg, Deborah, Chao, Bo, Berger, Allison J, Nakamura, Akito, Zhang, Yuhong, Song, Keli, Ward, Christine K., Proscurshim, Igor, Kumar, Shaji |
| المصدر: | Blood; November 2021, Vol. 138 Issue: 1, Number 1 Supplement 1 p2742-2742, 1p |
| مستخلص: | Background:SUMOylation, a post-translational modification analogous to ubiquitination, attaches a small, ubiquitin-like modifier (SUMO) to target proteins. SUMOylation plays a central role in the immune system by regulating type I interferon (IFN-I) expression, thereby functioning to constrain the innate immune response (Decque Nat Immunol2016), and limit tumor immune surveillance. The SUMOylation pathway is often overexpressed in multiple myeloma (MM) and is associated with poor outcomes (Driscoll Blood2010). |
| قاعدة البيانات: | Supplemental Index |
Full Text Finder | تدمد: | 00064971 15280020 |
|---|---|
| DOI: | 10.1182/blood-2021-148385 |